z-logo
Premium
Endothelial nitric oxide synthase polymorphism influences renal allograft outcome
Author(s) -
Uyar Murathan,
Sezer Siren,
Ozdemir Fatma Nurhan,
Kulah Eyup,
Arat Zubeyde,
Atac Fatma Belgin,
Haberal Mehmet
Publication year - 2014
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12302
Subject(s) - enos , medicine , gene polymorphism , allele , transplantation , endocrinology , nitric oxide synthase , gastroenterology , nitric oxide , gene , genetics , biology
Background Atherosclerotic lesions within the graft are considered to be a major cause of interstitial fibrosis/tubular atrophy (IF/TA). We evaluated the factors that influence the development of IF/TA and three‐ and five‐yr graft survival including nitric oxide synthase ( eNOS ) and angiotensin II type 1 and type 2 receptor gene polymorphism. Methods Seventy‐one male and 35 female patients (age: 34.9 ± 11.2 yr) who underwent living‐related renal transplantation were included. Angiotensin type 1 and type 2 receptor gene polymorphisms and eNOS intron 4 gene polymorphism were analyzed. The pre‐ and post‐transplant laboratory data, patient characteristics, acute rejection episodes, and presence of IF/TA were evaluated. Results Patients with the bb allele of eNOS gene had a lower prevalence of post‐transplant third year (12.6% and 38.5%, p = 0.005) and fifth year IF/TA (46.6% and 82.3%, p = 0.02) and a lower incidence of five‐yr graft failure (35.4% and 55.6%, p < 0.005). The eNOS gene polymorphism was independent and was the most prominent factor associated with third and fifth year IF/TA (p = 0.01, RR: 29.72, and p = 0.03, RR: 4.1, respectively). No significant relationship existed when angiotensin II gene polymorphisms were considered. Conclusions We concluded that recipient eNOS gene polymorphism can predict IF/TA, and the presence of the bb allele is associated with better graft outcome.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here